DRI Healthcare TRUST

thx Dan

So, this is essentially a drug royalty company. It collects royalties from pharmaceutical companies, and doesn't have to incur the costs and risks of developing the drugs. It's a fairly interesting concept.

The company has been around for a while but has a relatively short lifespan in terms of it being publicly traded. As a result, we have a lot of pro forma reporting in its statements, which does have its use cases in particular situations, but can mislead investors as it is simply a hypothetical result, based on optimal results.

The company seems cheap. Trading at only 11x trailing net earnings. This is probably a company I'd place on my watchlist and see how they perform as a publicly traded company over the next 3-4 quarters. Yes, there is the potential to miss the bottom here. But, I'd personally just like a bit more clarity.